Sotrovimab, the anti-viral medicine for COVID-19, is 100 per cent effective in preventing death, according to the latest study results released by MoHAP.
It showed that 97 per cent of the recipients recovered within 14 days and prevented ICU admission in 99 per cent of the cases.
The study was carried out between June 30 and July 13 in collaboration with the Abu Dhabi Department of Health and Dubai Health Authority (DHA).
Over 6,100 patients were given the anti-viral medicine, of which 52 per cent were aged 50 or above and had multiple pre-existing medical conditions.
The UAE was one of the first countries to receive the shipment of the medicine and had approved its use in June.


ADNOC L&S vessel sustains damage following attack
H.H. Sheikh Khaled, H.H. Sheikh Hamdan discuss key national priorities
Russia-Ukraine-US trilateral talks to resume on Wednesday in Abu Dhabi
UAE completes critical design review of 'Sirb-1' satellite
UAE conditionally approves new use of Ultomiris for kidney disease patients
H.H. Sheikh Hamdan approves Dubai Metro extension to Al Maktoum Airport
UAE Year Of Award celebrates stronger families, community values
UAE President highlights nation's resilience during 'recent challenges'
H.H. Sheikh Khaled approves second package of Emirati Family Growth Programme
Sharjah approves housing support for 1,100 families
Sheikh Abdullah attends third round of Russia-Ukraine-US trilateral talks
H.H. Sheikh Mohammed directs tents for 50,000 Gazans facing harsh weather
UAE postpones vehicle licensing limit for residents
New pedestrian bridge links Dubai Mall Metro Station and Coca-Cola Arena
High-achieving Union teams honoured at UAE Government Annual Meetings
Al Gergawi: UAE accelerates development with over AED 4 trillion in projects
Abu Dhabi launches lifestyle programme to help citizens get healthier
5 Esaad cards up for grabs in Dubai Police's 5-week traffic contest
